Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- US stock futures steady as oil jumps to two-week high ahead of key earnings
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's Russian supply announcements
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- Iren shares jump 5% in premarket trade on report of Anthropic AI cloud deal
| (NASDAQ: ARVN) | Delayed: 7.64 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.64 | 52 Week High | $ | |||
| Open | $7.64 | 52 Week Low | $ | |||
| Day High | $7.64 | P/E | N/A | |||
| Day Low | $7.64 | EPS | $ | |||
| Volume | 769 | |||||
